2023
Epidemiology of substance use and mental health disorders among forced migrants displaced from the MENAT region: A systematic review and meta-analysis protocol
Kazemitabar M, Nyhan K, Makableh N, Minahan-Rowley R, Ali M, Wazaify M, Tetrault J, Khoshnood K. Epidemiology of substance use and mental health disorders among forced migrants displaced from the MENAT region: A systematic review and meta-analysis protocol. PLOS ONE 2023, 18: e0292535. PMID: 37797050, PMCID: PMC10553213, DOI: 10.1371/journal.pone.0292535.Peer-Reviewed Original ResearchConceptsMental health disordersSubstance use disordersSystematic reviewRegistration IDHealth disordersJoanna Briggs Institute checklistBias 2 toolRisk of biasInternational Prospective RegisterDatabases of EmbaseMeta-analysis protocolJoanna Briggs InstituteComprehensive systematic reviewRandom-effects modelSystematic review protocolCochrane riskMEDLINE search strategySubgroup analysisProspective RegisterRisk factorsObservational studyUse disordersHealth providersIntervention studiesImproving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centers
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosisThe impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersGrief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications
Morford KL, Batchelor HM, Tetrault JM. Grief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications. Journal Of Addiction Medicine 2022, 16: 613-615. PMID: 35165230, DOI: 10.1097/adm.0000000000000976.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid overdose crisisOverdose crisisImmunodeficiency syndrome (AIDS) epidemicCare of peopleTreatment outcomesOverdose deathsUse disordersEmotional burdenSocial support networksContext of stigmaHarmful consequencesSupport networksRole of griefGriefPatientsOverdoseCliniciansIntegration of medication for opioid use disorder training into graduate nursing education
Barcelona V, Wischik DL, Marshall A, Tetrault JM. Integration of medication for opioid use disorder training into graduate nursing education. Nursing Forum 2022, 57: 869-873. PMID: 35616353, DOI: 10.1111/nuf.12753.Peer-Reviewed Original ResearchConceptsOpioid use disorderDrug Enforcement AdministrationIntegration of medicationPrescription of medicationsGeneral medical settingsHealth care providersMore health care providersOpioid overdose crisisGraduate nursing curriculumNurse practitioner studentsRelated complicationsMedicine cliniciansCare providersX-waiverUse disordersDisorder trainingInterprofessional partnershipsNursing educationOverdose crisisPractitioner studentsAdvanced practiceMedical settingsMedicationsCOVID-19 pandemicNP studentsPrimary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting
Haque LY, Butner JL, Shi JM, Henry S, Deng Y, Ciarleglio MM, Madden LM, Tetrault JM. Primary Care Associated With Follow Up Viral Load Testing in Patients Cured of Hepatitis C Infection With Direct Acting Antivirals at a Multidisciplinary Addiction Treatment Program: Insights From a Real-World Setting. Journal Of Addiction Medicine 2022, 16: 333-339. PMID: 34483278, PMCID: PMC9033626, DOI: 10.1097/adm.0000000000000910.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionUrine toxicology resultsDirect acting antiviralsViral load testingSubstance use disordersAddiction treatment programsHCV reinfectionActing antiviralsToxicology resultsUse disordersDirect acting antiviral therapyTreatment programReal-world clinical settingHCV reinfection ratesActing antiviral (DAA) therapyC virus infectionHepatitis C infectionMedical service useCohort of patientsPrimary medical careSubstance use statusAddiction treatment settingsQuality improvement initiativesHCV cureC infectionChapter 9 Addiction management in the outpatient setting
Shi J, Slocum B, Tetrault J, Yanagisawa K. Chapter 9 Addiction management in the outpatient setting. 2022, 169-187. DOI: 10.1016/b978-0-323-79016-1.00008-8.Peer-Reviewed Original ResearchOpioid use disorderNonmedical opioid useOpioid useUntreated opioid use disorderPain management strategiesCurrent treatment optionsOpioid overdose crisisPostoperative painOutpatient settingTreatment optionsRisk factorsGeneral practitionersHigh riskEarly deathUse disordersAddiction specialistsCurrent opioid overdose crisisMedical providersBrain physiologyInfectious diseasesAddiction managementOverdose crisisAffected individualsDisordersThoughtful approach
2021
Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach
Cohen SM, Weimer MB, Levander XA, Peckham AM, Tetrault JM, Morford KL. Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. Journal Of Addiction Medicine 2021, 16: 399-406. PMID: 34954746, DOI: 10.1097/adm.0000000000000945.Peer-Reviewed Original ResearchConceptsLow dose initiationFull opioid agonistsDose initiationOpioid withdrawal symptomsOpioid agonistsBuprenorphine doseWithdrawal symptomsHigh potency synthetic opioidsOpioid use disorderAppropriate clinical situationsMu-opioid receptorsBuprenorphine initiationOpioid withdrawalStarting doseOutpatient settingCare coordinationDose changesOverdose deathsCurrent evidenceUse disordersBuprenorphineTherapeutic levelsClinical situationsSynthetic opioidsNarrative reviewSOAPs and SUDs: Patients With Substance Use Disorders and What Clinicians Should Know About the Cures Act
Chan CA, Tetrault JM, Fiellin DA, Weimer MB. SOAPs and SUDs: Patients With Substance Use Disorders and What Clinicians Should Know About the Cures Act. Journal Of Addiction Medicine 2021, 16: 141-142. PMID: 34049315, DOI: 10.1097/adm.0000000000000879.Commentaries, Editorials and Letters
2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatmentSubstance Use Disorders in Recently Hospitalized Patients With Cirrhosis.
Haque LY, Jakab S, Deng Y, Ciarleglio MM, Tetrault JM. Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis. Journal Of Addiction Medicine 2020, 14: e337-e343. PMID: 32530887, PMCID: PMC9033633, DOI: 10.1097/adm.0000000000000677.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersAddiction treatmentAlcohol-related liver diseaseImpact of SUDHepatitis C infectionMedical record reviewMinority of patientsNumber of hospitalizationsRoutine clinical careAlcohol use disorderHepatology clinicC infectionCause mortalityConsecutive patientsMedian ageCommon etiologyLiver diseaseRecord reviewSignificant morbidityRetrospective studySUD careCirrhosisClinical careHospitalizationComputerized Cognitive Behavioral Therapy for Substance Use Disorders in a Specialized Primary Care Practice: A Randomized Feasibility Trial to Address the RT Component of SBIRT.
Tetrault JM, Holt SR, Cavallo DA, O'Connor PG, Gordon MA, Corvino JK, Nich C, Carroll KM. Computerized Cognitive Behavioral Therapy for Substance Use Disorders in a Specialized Primary Care Practice: A Randomized Feasibility Trial to Address the RT Component of SBIRT. Journal Of Addiction Medicine 2020, 14: e303-e309. PMID: 32371660, DOI: 10.1097/adm.0000000000000663.Peer-Reviewed Original ResearchConceptsSubstance use disordersComputerized cognitive behavioral therapySubstance useCognitive behavioral therapySelf-reported substance useUse disordersTechnology-based treatmentsPrimary care settingSubstance use outcomesIntegrated addictions treatmentTechnology-based interventionsBehavioral therapyPrimary care practicesOverall positive outcomeSUD interventionsBrief interventionUnhealthy alcohol useDays abstinentPositive outcomesUse outcomesCare settingsAlcohol useStandard careAddiction treatmentTreatment settings
2019
Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [Drug Alcohol Depend. 186 (2018) 171–174]
Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Corrigendum to “Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder” [Drug Alcohol Depend. 186 (2018) 171–174]. Drug And Alcohol Dependence 2019, 205: 107601. PMID: 31593815, DOI: 10.1016/j.drugalcdep.2019.107601.Peer-Reviewed Original ResearchThe Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortexIntegration of care for HIV and opioid use disorder
Oldfield B, Muñoz N, McGovern M, Funaro M, Villanueva M, Tetrault J, Edelman E. Integration of care for HIV and opioid use disorder. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30882491, PMCID: PMC6588508, DOI: 10.1097/qad.0000000000002125.Peer-Reviewed Original ResearchConceptsHIV care settingsCare settingsClinical benefitTreatment settingsSystematic reviewBuprenorphine/naloxoneOpioid use disorderProvision of medicationsIntegration of careAntiretroviral therapyOpioid useMedication adherencePROSPERO databaseOvid MEDLINETreatment strategiesObservational studyHIVUse disordersModerate riskBehavioral interventionsScreening strategyOUDRisk reductionTreatmentUnique studiesA randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results
Bernstein SL, Weiss J, DeWitt M, Tetrault JM, Hsiao AL, Dziura J, Sussman S, Miller T, Carpenter K, O’Connor P, Toll B. A randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results. Implementation Science 2019, 14: 8. PMID: 30670043, PMCID: PMC6343239, DOI: 10.1186/s13012-019-0856-8.Peer-Reviewed Original ResearchConceptsPatient's primary care providerPrimary care providersTobacco treatment medicationsElectronic health recordsTobacco use disorderQuit ratesTreatment medicationsProblem listCare providersUse disordersOne-year quit ratesState tobacco quitlineTobacco quit ratesPrescription of medicationsTobacco dependence treatmentProcess of careSingle hospital systemElectronic medical recordsInpatient electronic medical recordPatient's problem listSustained quittingAdult patientsControl patientsCurrent smokingHospitalized smokers
2018
“No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder
Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, Tetrault JM, Edelman E. “No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. Journal Of Substance Use And Addiction Treatment 2018, 97: 28-40. PMID: 30577897, DOI: 10.1016/j.jsat.2018.11.007.Peer-Reviewed Original ResearchConceptsOpioid use disorderIntegration of HIVUse disordersClinical staffCare of HIVCommunity-based participatory research principlesBehavioral health integrationImproved patient outcomesEvidence-based treatmentsDiverse care settingsParticipatory research principlesPrimary carePatient outcomesPatient-centered policiesCare settingsHealth integrationHIVQualitative studyStages of changeClinic leadershipCare instrumentIntegrated carePatientsBehavioral healthMeasures of qualityOffice-Based Addiction Treatment in Primary Care Approaches That Work
Edelman EJ, Oldfield BJ, Tetrault JM. Office-Based Addiction Treatment in Primary Care Approaches That Work. Medical Clinics Of North America 2018, 102: 635-652. PMID: 29933820, DOI: 10.1016/j.mcna.2018.02.007.Peer-Reviewed Original ResearchConceptsPrimary careUse disordersPrimary care-based approachSubstance useHuman immunodeficiency virusOpioid use disorderEvidence-based treatmentsCounseling-based interventionsSubstance use disordersImmunodeficiency virusSpecialty settingsMultidisciplinary teamCare-based approachHealth disparitiesAddiction treatmentCareDisordersOptimal approachImportant settingTreatmentPharmacotherapySettingAddressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder
Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder. Drug And Alcohol Dependence 2018, 186: 171-174. PMID: 29579725, DOI: 10.1016/j.drugalcdep.2017.12.040.Peer-Reviewed Original ResearchConceptsOngoing illicit drug usePatient-provider relationshipOpioid use disorderIllicit drug useUse disordersUrine adulterationTreatment planDrug useQuantitative urine testingMethadone treatment programsSubstance use disordersNorbuprenorphine levelsUrine buprenorphineUrine testingPatientsTreatment programNonjudgmental approachUrine samplesTherapeutic allianceDiscordant levelsBuprenorphineDisordersUrineNorbuprenorphineLevels